Obstructive Sleep Apnea Drugs Market: By Drugs (CNS stimulants, Benzodiazepines, and Hypnotics), By Distribution Channel (Hospital pharmacies, Retail Pharmacies, and Online Pharmacies) and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Obstructive Sleep Apnea Drugs Market size was valued at USD 9,153.7 million in 2022 and is poised to grow at a CAGR of 3.7% from 2023-2029. Sleep apnea is a sleeping disease caused by irregular breathing and oxygen deprivation of the brain. According to a study published in 2020 by the American Sleep Association, between 50 and 70 million people in the United States suffer from sleep disorders. According to research published by the American Sleep Association in 2020, an estimated 50 million to 70 million persons in the United States suffer from sleep disturbances. Furthermore, the Canadian Respiratory Journal reported in 2014 that around 5.4 million persons in Canada had been diagnosed with sleep apnea or were at risk of acquiring Obstructive sleep apnea. A surge in the prevalence of sleep apnea is majorly driving the growth of the sleep apnea treatment market.

Furthermore, the growing geriatric population, rising lifestyle changes, growing home care acceptance coupled with the awareness of sleepwear disorders, improving healthcare infrastructure, an introduction of new technologies, and innovative products are expected to fuel the growth of the sleep apnea treatment market. The massive pool of undiagnosed patients with sleep apnea holds tremendous potential for the sleep apnea devices market. The older population has a significant prevalence of sleep apnea, which is underdiagnosed due to lack of knowledge and the disease's non-specific presentation. Sleep disturbances are projected to become more common as the senior population grows as life expectancy increases. According to the WHO, the global population of persons aged 60 and more is predicted to reach 2.0 billion by 2050 in 2018. Because this population group is more susceptible to sleep apnea, an increase in the senior population is projected to enhance the use of these devices. Furthermore, because comorbidities linked with sleep apnea are high among the elderly, the prevalence of sleep apnea is rising in the geriatric population.

Obstructive Sleep Apnea Drugs Market Key Developments:

  • In May 2022, Axsome Therapeutics, Inc. a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced the completion of its U.S. acquisition of Sunosifrom Jazz Pharmaceuticals. Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA). The ex-U.S. transaction is expected to close within 60 days.

Global Obstructive Sleep Apnea Drugs Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

3.7%

Largest Market

North America

Fastest Growing Market

Europe

Obstructive Sleep Apnea Drugs Market Dynamics

The enormous pool of undiagnosed sleep apnea patients, growing knowledge about the adverse effects of untreated sleep apnea, and an increasing number of players venturing into the sleep apnea industry are driving market expansion. With the ongoing awareness campaigns and efforts, it is envisaged that a new patient base will be diagnosed and treated for sleep apnea. However, the sleep apnea treatment market is projected to be hampered by tight regulatory procedures, pharmacological side effects, and intense market rivalry.

The prevalence rate of obstructive sleep apnea (OSA) is increasing rapidly across the globe which increases risk of road traffic, work-related accidents, cardiovascular diseases and strokes. As per the National Commission on Sleeping Disorders Research, globally about 38,000 deaths are accounting annually owing to the cardiovascular problems associated with sleep apnea. OSA is also correlated with heart failure which is 12-16% more prevalent in OSA patients. It has also been observed that approximately 60-70% of OSA patients are obese. Increasing prevalence of Obstructive Sleep Apnea is associated with number of cardiac and metabolic diseases. However, awareness, diagnosis, and treatment of Obstructive Sleep Apnea could offer significant savings to the patient  

Global Obstructive Sleep Apnea Drugs Market Segmentation

By Drugs

  • CNS stimulants
  • Benzodiazepines
  • Hypnotics

By Distribution Channel

  • Hospital pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Frequently Asked Questions

The obstructive sleep apnea drugs market size was valued at USD 9,153.7 million in 2022

Rising Prevalence of Sleep Apnea and Upsurge in Geriatric Population

Europe is the fastest-growing for obstructive sleep apnea drugs market

Key Features of the Report

  • The obstructive sleep apnea drugs market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1. Executive Summary
2. Global Obstructive Sleep Apnea Drugs Market Introduction 
2.1.Global Obstructive Sleep Apnea Drugs Market  - Taxonomy
2.2.Global Obstructive Sleep Apnea Drugs Market  - Definitions
2.2.1.Drugs
2.2.2.Distribution Channel
2.2.3.Region
3. Global Obstructive Sleep Apnea Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Obstructive Sleep Apnea Drugs Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Obstructive Sleep Apnea Drugs Market  By Drugs, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. CNS stimulants
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Benzodiazepines
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Hypnotics
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
6. Global Obstructive Sleep Apnea Drugs Market  By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Hospital pharmacies
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Retail Pharmacies
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Online Pharmacies
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7. Global Obstructive Sleep Apnea Drugs Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Europe
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Asia Pacific (APAC)
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Middle East and Africa (MEA)
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. Latin America
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
8. North America Obstructive Sleep Apnea Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. Drugs Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.1.1.CNS stimulants
8.1.2.Benzodiazepines
8.1.3.Hypnotics
8.2.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.2.1.Hospital pharmacies
8.2.2.Retail Pharmacies
8.2.3.Online Pharmacies
8.3.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.3.1.United States of America (USA)
8.3.2.Canada
9. Europe Obstructive Sleep Apnea Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. Drugs Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.CNS stimulants
9.1.2.Benzodiazepines
9.1.3.Hypnotics
9.2.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Hospital pharmacies
9.2.2.Retail Pharmacies
9.2.3.Online Pharmacies
9.3.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Germany
9.3.2.France
9.3.3.Italy
9.3.4.United Kingdom (UK)
9.3.5.Spain
9.3.6.Rest of EU
9.3.7.
10. Asia Pacific (APAC) Obstructive Sleep Apnea Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Drugs Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.CNS stimulants
10.1.2.Benzodiazepines
10.1.3.Hypnotics
10.2.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Hospital pharmacies
10.2.2.Retail Pharmacies
10.2.3.Online Pharmacies
10.3.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.China
10.3.2.India
10.3.3.Australia and New Zealand (ANZ)
10.3.4.Japan
10.3.5.Rest of APAC
11. Middle East and Africa (MEA) Obstructive Sleep Apnea Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Drugs Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.CNS stimulants
11.1.2.Benzodiazepines
11.1.3.Hypnotics
11.2.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Hospital pharmacies
11.2.2.Retail Pharmacies
11.2.3.Online Pharmacies
11.3.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.GCC Countries
11.3.2.South Africa
11.3.3.Rest of MEA
12. Latin America Obstructive Sleep Apnea Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Drugs Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.CNS stimulants
12.1.2.Benzodiazepines
12.1.3.Hypnotics
12.2.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Hospital pharmacies
12.2.2.Retail Pharmacies
12.2.3.Online Pharmacies
12.3.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Brazil
12.3.2.Mexico
12.3.3.Rest of LA
13. Competition Landscape
13.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
13.2.1.Biogen, Inc (U.S).
13.2.2.Pfizer, Inc. (U.s)
13.2.3.Johnson & Johnson Services, Inc. (U.S)
13.2.4.Otsuka America Pharmaceutical, Inc. (U.S)
13.2.5.Eli Lilly & Company (U.S)
13.2.6.Merck & Co., Inc. (U.S)
13.2.7.AstraZeneca (UK)
13.2.8.Novartis AG (Switzerland)
14. Research Methodology 
15. Appendix and Abbreviations 
  • Biogen, Inc (U.S).
  • Pfizer, Inc. (U.s)
  • Johnson & Johnson Services, Inc. (U.S)
  • Otsuka America Pharmaceutical, Inc. (U.S)
  • Eli Lilly & Company (U.S)
  • Merck & Co., Inc. (U.S)
  • AstraZeneca (UK)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Shire Plc. (Ireland)

Adjacent Markets